What if an everyday undergarment could identify decompensating heart failure weeks in advance of hospitalizing events?
Congestive Heart Failure is the chronic disease management case of our time.
The ability to remotely monitor Congestive Heart Failure (CHF) patients and keep them out of the hospital is essential in today's world of value- or outcomes-based medicine. Not only does CHF account for a large and growing population of the chronically ill (6mm diagnosed Americans w/ ~700K new U.S. cases annually), but it is also a systemic financial burden on providers with a ~25-40% rate of recidivism within 30 days of discharge. $31bn in annual cost is associated with CHF management with $17bn of the spend coming from taxpayers / medicare, which is estimated to balloon to $100bn by 2030. Because of this explosion in patient growth and associated costs, the burden of risk now falls on hospital providers as CMS care requirements and reimbursement penalties are being instituted in an effort to curb increases in hospital admissions.
But most importantly, Congestive Heart Failure is a devastating disease for the patient's quality of life due to an unpredictable shortness of breath, inability to accomplish daily activities and frequent hospitalizations to reduce fluid accumulation in the lungs. The current standard of care does not reach the majority of CHF patients and these patients truly suffer in managing this ever-worsening condition.
Solving this unmet economic and clinical need for CHF requires a low cost, non-invasive, easy-to-use and highly efficacious solution that improves care coordination, slows progression and reduces hospital readmissions.
Utilizing proprietary FDA-cleared cloth-based nanosensors, the Nanowear CHF monitoring device, SimpleSense, is the first-of-its-kind, non-invasive, undergarment solution worn by patients following discharge of a CHF-related hospitalization event. The device captures and transmits multiple parameters -- ECG, Heart Rate Variability, Respiratory Rate, Impedance Cardiography (Stroke Volume and Cardiac Output), Thoracic impedance, sound/ cardio-phonography (S3 murmurs), and actigraphy -- to a cloud-based environment, providing access and updates to medical professionals for assessment of patient health and progress. Data aggregation and daily algorithmic scoring will alert care management teams of decompensating heart failure weeks in advance of hospitalizing events, ultimately enabling actionable changes to patient care during normal business hours while patients are at home. Nanowear's multi-parameter, multi-variable scoring thesis was proven by Boston Scientific in recent HeartLogic / MultiSENSE trials where an algorithmic score of 5 metrics captured by an implantable device showed ~75% success in reducing heart failure-related events.
SimpleSense will increase patient outcomes and reduce recidivism following discharge through the ability to promote real-time medication titration, coordinate care plan modifications, and schedule outpatient visits ultimately being the 1st solution and platform that actually reaches the 4 key stakeholders (Patients, Physicians / Care teams, CMS / Payors, and Hospital Providers)
Most importantly, SimpleSense will allow the millions of CHF patients to live their lives with confidence and return the quality of life they deserve.
Easy one-click social registrationIs this safe?
We only receive the minimum information necessary to verify your account. We never get access to your friends/contacts or your profile, and we never post on your behalf. Your social account is used for logging in only.ORRegister via email
Send me updates on this Contest
In order to ensure a fair voting process and to make sure that no one votes more than once, we ask that you register either with a social networking account (easiest, only requires one click) or by registering with your email address (this will require you to click on a verification email that we will send you).
You only need to register once.